Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(0.78) Estimate, Sales $89.565K Miss $290.000K Estimate

Author: Benzinga Newsdesk | August 08, 2024 06:30am
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.78) by 28.21 percent. This is a 17.65 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $89.565 thousand which missed the analyst consensus estimate of $290.000 thousand by 69.12 percent.

Posted In: LPCN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist